A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the
recommended Phase 2 Dose (RP2D) of NKT2152. The Phase 2 portion will evaluate the efficacy of
NKT2152 in ccRCC.